Funding Opportunities

NIH Funding Opportunities

Notice of Correction to Application Package for PA-14-037 "Women and Sex/Gender Differences in Drug and Alcohol Abuse/Dependence (R03)"
Notice NOT-DA-14-051 from the NIH Guide for Grants and Contracts
Mon, 20 Oct 2014 02:38:26 EST

Notice of Participation of NIMHD in PA-13-119 "Mechanisms, Models, Measurement, and Management in Pain Research (R21)"
Notice NOT-MD-14-008 from the NIH Guide for Grants and Contracts
Mon, 20 Oct 2014 02:52:10 EST

Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction (R01)
Funding Opportunity RFA-DK-14-023 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to support innovative research in humans to elucidate the role of HIV infection, including relevant host conditions or antiretroviral therapy, on metabolic and endocrine dysfunction, as well as to support innovative research delineating the pathophysiology, etiology, risk or protective factors, and potential strategies to prevent, treat, or reverse endocrine and metabolic dysfunction in HIV-infected individuals. Proposed projects must involve human subjects with HIV infection or materials or data from HIV-infected individuals. Proposed projects must also be related to the mission of the Division of Diabetes, Endocrinology, and Metabolic Diseases within NIDDK (DEM/NIDDK).
Mon, 20 Oct 2014 06:19:23 EST

Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)
Funding Opportunity RFA-FD-15-001 from the NIH Guide for Grants and Contracts. The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. Applicants must include in the application's Background and Significance section documentation to support the assertion that the orphan disease or condition to be studied is a rare disease or condition and an explanation of how the proposed study will either help support product approval or provide essential data needed for product development.
Mon, 20 Oct 2014 03:30:12 EST

NIH Director's Early Independence Awards (DP5)
Funding Opportunity RFA-RM-14-004 from the NIH Guide for Grants and Contracts. The NIH Directors Early Independence Award Program supports exceptional investigators who wish to pursue independent research directly after completion of their terminal doctoral/research degree or clinical residency, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career.
Tue, 21 Oct 2014 01:06:24 EST

Physical Sciences-Oncology Network (PS-ON): Physical Sciences-Oncology Projects (PS-OP) (U01)
Funding Opportunity PAR-15-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the PS-OPs is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming small transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.
Tue, 21 Oct 2014 01:47:51 EST